Patrys Limited
Records under this name other than patents Patrys Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,947,812 | Neoplasm specific antibodies and uses thereof Lapsed on the fee record Ended May 24, 2023 · From the USPTO record | Lapsed on the fee record | Ended May 24, 2023 | From the USPTO record |
| US 8,741,296 | Adenocarcinoma specific antibody SAM-6, and uses thereof Formerly held Lapsed on the fee record Ended Jun 3, 2022 · From the USPTO record | Lapsed on the fee record | Ended Jun 3, 2022 | From the USPTO record |
| US 8,562,995 | Neoplasm specific antibodies and uses thereof Formerly held Lapsed on the fee record Ended Oct 22, 2021 · From the USPTO record | Lapsed on the fee record | Ended Oct 22, 2021 | From the USPTO record |
| US 9,783,599 | Lm-Antibodies, Functional Fragments, LM-1 Target Antigen, and Methods for Making and Using Same Lapsed on the fee record Ended Oct 10, 2021 · High confidence | Lapsed on the fee record | Ended Oct 10, 2021 | High confidence |
| US 8,163,552 | Adenocarcinoma specific antibody SAM-6, and uses thereof Formerly held Lapsed on the fee record Ended Apr 24, 2020 · From the USPTO record | Lapsed on the fee record | Ended Apr 24, 2020 | From the USPTO record |
| US 9,273,125 | Human monoclonal antibody having fat-reducing effect Lapsed on the fee record Ended Mar 1, 2020 · From the USPTO record | Lapsed on the fee record | Ended Mar 1, 2020 | From the USPTO record |
| US 8,124,080 | Human monoclonal antibody having fat-reducing effect Lapsed on the fee record Ended Feb 28, 2020 · From the USPTO record | Lapsed on the fee record | Ended Feb 28, 2020 | From the USPTO record |
| US 9,265,817 | Pat-LM1 Epitopes and Methods for Using Same Lapsed on the fee record Ended Feb 23, 2020 · High confidence | Lapsed on the fee record | Ended Feb 23, 2020 | High confidence |
| US 7,767,787 | Substance for obtaining highly effective tumor medications as well as a process Lapsed on the fee record Ended Aug 3, 2018 · From the USPTO record | Lapsed on the fee record | Ended Aug 3, 2018 | From the USPTO record |
| US 7,772,372 | Neoplasm specific antibodies and uses thereof Lapsed on the fee record Ended Aug 10, 2014 · From the USPTO record | Lapsed on the fee record | Ended Aug 10, 2014 | From the USPTO record |